Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
出版年份 2022 全文链接
标题
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-03-12
DOI
10.1186/s13045-022-01242-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
- (2022) A. Filippone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
- (2022) Caicun Zhou et al. LANCET ONCOLOGY
- Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
- (2022) Yuichiro Doki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
- (2022) Zhi Qi et al. Nature Communications
- CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer
- (2021) Antonio Passaro et al. LANCET ONCOLOGY
- Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
- (2021) Sadna Budhu et al. Cell Reports
- PD‐L1 positively regulates MET phosphorylation through inhibiting PTP1B
- (2021) Shangyun Lu et al. CANCER SCIENCE
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma
- (2021) Lei Guo et al. LIFE SCIENCES
- Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
- (2021) Xiaoming Dai et al. MOLECULAR CELL
- Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
- (2021) Zowi R. Huinen et al. Nature Reviews Clinical Oncology
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- Aldehyde Dehydrogenase 2 Mediates Alcohol‐Induced Colorectal Cancer Immune Escape through Stabilizing PD‐L1 Expression
- (2021) Hong Zhang et al. Advanced Science
- Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
- (2021) Qiaoqi Sui et al. Journal for ImmunoTherapy of Cancer
- Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
- (2021) Lu Cao et al. Journal of Clinical Medicine
- Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
- (2021) Shangqin Sun et al. Cancers
- The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development
- (2021) Sandra Majo et al. Cancers
- Patient-Derived Cancer Organoids as Predictors of Treatment Response
- (2021) Maikel Verduin et al. Frontiers in Oncology
- Engineering Endogenous Tumor‐Associated Macrophage‐Targeted Biomimetic Nano‐RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo‐Immunotherapy
- (2021) Yupeng Wang et al. ADVANCED MATERIALS
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
- (2021) Yujue Wang et al. CANCER CELL
- Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
- (2021) Yan Lan et al. CANCER CELL
- M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
- (2021) Xinyao Qiu et al. CANCER RESEARCH
- Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
- (2021) Kazuhiro Koikawa et al. CELL
- Phase I Study of Stereotactic Body Radiotherapy Plus Nivolumab and Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors
- (2021) Corey C. Foster et al. CLINICAL CANCER RESEARCH
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
- (2021) Xiaoxiang Zhou et al. LANCET ONCOLOGY
- Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
- (2021) Benjamin C. Creelan et al. NATURE MEDICINE
- Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways
- (2021) Zhen Xiang et al. ONCOGENE
- Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
- (2021) Janna Krueger et al. PLoS One
- Developmental chromatin programs determine oncogenic competence in melanoma
- (2021) Arianna Baggiolini et al. SCIENCE
- Opposing roles of the immune system in tumors
- (2021) Won Jin Ho et al. SCIENCE
- Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
- (2021) Amaia Martinez-Usatorre et al. Science Translational Medicine
- A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
- (2021) Cecile Geuijen et al. Nature Communications
- Establishment of patient‐derived organotypic tumor spheroid models for tumor microenvironment modeling
- (2021) Hye Kyung Hong et al. Cancer Medicine
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
- (2021) Salma K. Jabbour et al. JAMA Oncology
- MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
- (2021) Si-Yu Wu et al. Journal for ImmunoTherapy of Cancer
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
- (2021) Yuanyuan Zhang et al. CANCER CELL
- The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1
- (2021) Hongzhong Li et al. CANCER CELL
- Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids
- (2021) Vivien Koh et al. CANCER LETTERS
- Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
- (2021) Khiem C. Lam et al. CELL
- Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
- (2021) Joseph J. Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
- (2021) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study
- (2021) David C Qian et al. LANCET ONCOLOGY
- Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
- (2021) Hussein A Tawbi et al. LANCET ONCOLOGY
- Mutant clones in normal epithelium outcompete and eliminate emerging tumours
- (2021) B. Colom et al. NATURE
- The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
- (2021) Yelena Y. Janjigian et al. NATURE
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- (2021) Julie Westerlin Kjeldsen et al. NATURE MEDICINE
- Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
- (2021) Clemens Hinterleitner et al. Nature Communications
- An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
- (2021) Shuguang Zuo et al. Journal for ImmunoTherapy of Cancer
- Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids
- (2021) Qingda Meng et al. Journal for ImmunoTherapy of Cancer
- Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids
- (2021) Jayati Chakrabarti et al. Cancers
- Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy
- (2021) Kewen Lei et al. Nature Biomedical Engineering
- Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells
- (2020) Haifang Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
- (2020) Rebecca A. Luchtel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High-dose vitamin C enhances cancer immunotherapy
- (2020) Alessandro Magrì et al. Science Translational Medicine
- Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
- (2020) Alok Kumar et al. eLife
- Molecular mechanism of SHP2 activation by PD-1 stimulation
- (2020) M. Marasco et al. Science Advances
- Acquired Resistance to Immune Checkpoint Inhibitors
- (2020) Adam J. Schoenfeld et al. CANCER CELL
- Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study
- (2020) Giovanni Lo Re et al. CYTOKINE
- Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases
- (2020) Lin Zhang et al. Science Translational Medicine
- The Role of PD-1 in Acute and Chronic Infection
- (2020) Jil M. Jubel et al. Frontiers in Immunology
- Master protocols in immuno-oncology: do novel drugs deserve novel designs?
- (2020) Luca Mazzarella et al. Journal for ImmunoTherapy of Cancer
- Characterization of human cancer xenografts in humanized mice
- (2020) Jonathan Rios-Doria et al. Journal for ImmunoTherapy of Cancer
- Ubiquitin C‐terminal hydrolase L1 promotes expression of programmed cell death‐ligand 1 in non‐small‐cell lung cancer cells
- (2020) Rudi Mao et al. CANCER SCIENCE
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Fasting-mimicking diet and hormone therapy induce breast cancer regression
- (2020) Irene Caffa et al. NATURE
- Probiotics in microbiome ecological balance providing a therapeutic window against cancer
- (2020) Nirmala Sehrawat et al. SEMINARS IN CANCER BIOLOGY
- Multistage Sensitive NanoCRISPR Enable Efficient Intracellular Disruption of Immune Checkpoints for Robust Innate and Adaptive Immune Coactivation
- (2020) Ning Wang et al. ADVANCED FUNCTIONAL MATERIALS
- Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX‐2 and PD‐L1
- (2020) Suxing Jin et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Challenges and Opportunities for Pancreatic Cancer Immunotherapy
- (2020) Adham S. Bear et al. CANCER CELL
- Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion
- (2020) Florida Voli et al. CANCER RESEARCH
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
- (2020) Md Amir Hossain et al. MEDICINAL RESEARCH REVIEWS
- Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
- (2020) Hye-Jung Kim et al. TRENDS IN IMMUNOLOGY
- Toll-Like Receptor 9 Agonists in Cancer
- (2020) Lilit Karapetyan et al. OncoTargets and Therapy
- Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma
- (2020) Changrong Wang et al. BIOMATERIALS
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial
- (2020) Makoto Nishio et al. Journal of Thoracic Oncology
- KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity
- (2020) Xizi Jiang et al. Cell and Bioscience
- The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
- (2020) Hui Li et al. Advanced Science
- Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling
- (2020) Christophe Glorieux et al. Redox Biology
- Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma
- (2020) Loryn Holokai et al. Cancers
- Physical Plasma-Treated Skin Cancer Cells Amplify Tumor Cytotoxicity of Human Natural Killer (NK) Cells
- (2020) Ramona Clemen et al. Cancers
- Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
- (2019) Wang Manni et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1
- (2019) Emma Eriksson et al. JOURNAL OF IMMUNOLOGY
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
- (2019) Loryn Holokai et al. PLoS Pathogens
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
- (2019) Hyun Lee et al. MOLECULES
- Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC
- (2019) Fabrice Barlesi et al. Journal of Thoracic Oncology
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
- (2019) Bo Gong et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
- (2019) Jing Li et al. Future Oncology
- Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis
- (2019) Andrew M Frederickson et al. Immunotherapy
- FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
- (2019) Piao Li et al. JOURNAL OF IMMUNOLOGY
- Development of the Inhibitors that Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
- (2019) Guzik et al. MOLECULES
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
- (2019) Alfredo Addeo et al. Frontiers in Oncology
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
- (2019) Carminia Maria Della Corte et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract
- (2019) Kiichiro Teruya et al. Marine Drugs
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Vitamin C Loaded Poly(urethane-urea)/ZnAl-LDH Aligned Scaffolds Increase Proliferation of Corneal Keratocytes and Up-Regulate Vimentin Secretion
- (2019) Mojgan Moghanizadeh-Ashkezari et al. ACS Applied Materials & Interfaces
- Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer
- (2019) Bin Liu et al. Acta Biomaterialia
- The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
- (2019) Jiajing Cai et al. OncoTargets and Therapy
- The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
- (2019) Weiting Qin et al. Frontiers in Immunology
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
- (2019) Elliot A. Philips et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
- (2019) John Kwon et al. Cancer Discovery
- Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression
- (2019) Man-Chin Chen et al. Cancers
- The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis
- (2019) Xiaobo Li et al. Cells
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Serotonin and human cancer: A critical view
- (2018) Denis Sarrouilhe et al. BIOCHIMIE
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
- (2018) Chia-Wei Li et al. CANCER CELL
- EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells
- (2018) Yang Wang et al. CELL CYCLE
- Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
- (2018) Xiaoqing Zhang et al. Cellular & Molecular Immunology
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
- (2018) John A. Thompson Journal of the National Comprehensive Cancer Network
- Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
- (2018) LiJun Xu et al. Molecular Oncology
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
- (2018) Mirjana Efremova et al. Nature Communications
- Nivolumab plus Ipilimumab Achieves Responses in dMMR/MSI-H Tumors
- (2018) Cancer Discovery
- Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes
- (2018) Konrad Gabrusiewicz et al. OncoImmunology
- Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
- (2018) Yiwen Li et al. Journal for ImmunoTherapy of Cancer
- The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
- (2018) Samuel F. Bakhoum et al. CELL
- Role of hypoxia-induced exosomes in tumor biology
- (2018) Chuchu Shao et al. Molecular Cancer
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
- (2018) Anchalee Rawangkan et al. MOLECULES
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma
- (2018) Hailong Ma et al. BRITISH JOURNAL OF CANCER
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Organoid Modeling of the Tumor Immune Microenvironment
- (2018) James T. Neal et al. CELL
- The brain–immune cells axis controls tissue specific immunopathology
- (2018) Maxi Heyner et al. Cellular & Molecular Immunology
- Undo the brake of tumour immune tolerance with antibodies, peptides and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells
- (2018) Wenyi Gu et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy
- (2018) Gang Shi et al. MOLECULAR THERAPY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Application of atomic force microscopy in cancer research
- (2018) Xiangying Deng et al. JOURNAL OF NANOBIOTECHNOLOGY
- Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
- (2018) George Fromm et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy of cancers comes of age
- (2017) Hila Yousefi et al. Expert Review of Clinical Immunology
- Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
- (2017) Xun Wang et al. IMMUNOLOGY LETTERS
- Targeting Immune Checkpoints in Cancer Therapy
- (2017) Suzanne L. Topalian JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
- (2017) Daniel Yee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer
- (2017) Xiaomei Gong et al. Journal of Thoracic Oncology
- PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
- (2017) Tim Wartewig et al. NATURE
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1
- (2017) Gang Chen et al. NATURE NEUROSCIENCE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
- (2017) J Wang et al. ONCOGENE
- Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
- (2017) Krzysztof M. Zak et al. STRUCTURE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
- (2017) Ming Jing Shen et al. Oncotarget
- The role of exosomal non-coding RNAs in cancer metastasis
- (2017) Jin-Peng Wang et al. Oncotarget
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Role of tumor microenvironment in tumorigenesis
- (2017) Maonan Wang et al. Journal of Cancer
- The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
- (2017) Howard Y. Li et al. Cancer Immunology Research
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy
- (2016) Panpan Zhang et al. CANCER SCIENCE
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
- (2016) Weimin Wang et al. CELL
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
- (2016) Andy J. Minn et al. CELL
- MYC — a thorn in the side of cancer immunity
- (2016) Stefani Spranger et al. CELL RESEARCH
- Dual Faces of IFN in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
- (2016) M. Mandai et al. CLINICAL CANCER RESEARCH
- Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8 + T Cell Exhaustion
- (2016) Bertram Bengsch et al. IMMUNITY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Organoids: A historical perspective of thinking in three dimensions
- (2016) Marina Simian et al. JOURNAL OF CELL BIOLOGY
- Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory
- (2016) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
- (2016) Tessa Gargett et al. MOLECULAR THERAPY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation
- (2016) Jonathan T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy for lung cancer
- (2016) Antonius Steven et al. RESPIROLOGY
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial
- (2016) Joanna E. Long et al. VACCINE
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
- (2016) Hidetoshi Sumimoto et al. PLoS One
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Targeting immune checkpoints: New opportunity for mesothelioma treatment?
- (2015) Elly Marcq et al. CANCER TREATMENT REVIEWS
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Extracellular vesicles shuffling intercellular messages: for good or for bad
- (2015) Alessandra Lo Cicero et al. CURRENT OPINION IN CELL BIOLOGY
- The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma
- (2015) Natalie Spaccarelli et al. DERMATOLOGIC CLINICS
- Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
- (2015) Timothy J. Daskivich et al. EUROPEAN UROLOGY
- Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
- (2015) Sanja Stevanović et al. JOURNAL OF CLINICAL ONCOLOGY
- Human PD-1 binds differently to its human ligands: A comprehensive modeling study
- (2015) Clement Viricel et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
- (2015) Ahmad A. Tarhini et al. Journal of Translational Medicine
- Programmed cell death-1 inhibition in lymphoma
- (2015) Eliza A Hawkes et al. LANCET ONCOLOGY
- Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells
- (2015) Abdullah Alsuliman et al. Molecular Cancer
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
- (2015) E. Vacchelli et al. SCIENCE
- New immunotherapies targeting the PD-1 pathway
- (2015) Jordan M. Chinai et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Several immune escape patterns in non-Hodgkin's lymphomas
- (2015) Camille Laurent et al. OncoImmunology
- Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?
- (2015) Guido Kroemer et al. OncoImmunology
- The role of serotonin and its receptors in activation of immune responses and inflammation
- (2014) M. S. Shajib et al. Acta Physiologica
- PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
- (2014) Shenyou Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
- (2014) Raja Rekik et al. Cellular & Molecular Immunology
- Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients
- (2014) Andreas Pircher et al. LUNG CANCER
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
- (2014) Hatem Soliman et al. PLoS One
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
- (2013) Y. Liu et al. JOURNAL OF NEUROSCIENCE
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
- (2013) Nikolaos Patsoukis et al. MOLECULAR AND CELLULAR BIOLOGY
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Role of the PD-1 Pathway in the Immune Response
- (2012) L. V. Riella et al. AMERICAN JOURNAL OF TRANSPLANTATION
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung
- (2012) Jennifer M. Boland et al. Clinical Lung Cancer
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion
- (2011) Kimberly A. Hofmeyer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- PD-L2 is expressed on activated human T cells and regulates their function
- (2011) Nassima Messal et al. MOLECULAR IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
- (2010) Elias A Said et al. NATURE MEDICINE
- PD-1 on dendritic cells impedes innate immunity against bacterial infection
- (2009) S. Yao et al. BLOOD
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+
- (2009) Karen S. Sfanos et al. PROSTATE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Interferon-sensitive response element (ISRE) is mainly responsible for IFN-α-induced upregulation of programmed death-1 (PD-1) in macrophages
- (2008) Hae-Yun Cho et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started